Record: 21

03/24/2021

Company Report

Pages: 8

Spotlight On BXC9930, Early Success for Factor D Inhibition; PT to $19

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Record: 22

02/26/2021

Company Report

Pages: 7

Orladeyo Three-Pronged Commercial Strategy With BCX9930 in its Wake

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Record: 23

12/07/2020

Company Report

Pages: 7

Orladeyo Approval Paves Way for Oral HAE Therapy; PT to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Record: 24

11/06/2020

Company Report

Pages: 6

Orladeyo Strategy In-Place Awaiting Approvals; With Broad Early Pipeline In Tow

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Record: 25

10/01/2020

Daily Note

Pages: 4

Our Thoughts on BCX9930 Data Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Record: 26

08/07/2020

Company Report

Pages: 6

Focus Remains on Oraldeyo Approval in 4Q20, With Underappreciated COVID-19 Play; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Record: 27

03/06/2020

Company Report

Pages: 6

With Potential Berotralstat Approval on 2020 Horizon

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Record: 28

01/27/2020

Daily Note

Pages: 4

BCX9930 Complement Inhibitor Program Can Provide Traction for Deeper Developmental Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Record: 29

11/07/2019

Company Report

Pages: 6

Positive 48-Week Durability From APeX-2

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Record: 30

10/29/2019

Daily Note

Pages: 4

Positive Phase 1 BCX9930 Data Paves Way for PoC in PNH Patients; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Record: 31

08/07/2019

Company Report

Pages: 5

NDA Is Underway While We Reframe the Commercial Potential; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Record: 32

05/22/2019

Daily Note

Pages: 4

Our Thoughts and KOL Feedback Following the ApeX-2 Topline; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Record: 33

05/09/2019

Company Report

Pages: 7

KOL Feedback Previews the Upcoming ApeX-2 Data in HAE; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Record: 34

03/05/2019

Company Report

Pages: 6

Underappreciated Discovery Platform Continues to Prove Fruitful While HAE Timelines Remain In-tact

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Record: 35

02/26/2019

Daily Note

Pages: 4

Oral Treatment for Acute HAE Attacks Is Ready for Phase 3

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Record: 36

11/07/2018

Company Report

Pages: 6

Continue to Be Constructive Ahead of 2019 Clinical Catalysts; Reit Buy and $13PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Record: 37

09/05/2018

Daily Note

Pages: 3

We Find Zenith Results Satisfying; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Record: 38

09/05/2018

Company Report

Pages: 4

We Find Zenith Results Satisfying; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Record: 39

08/13/2018

Company Report

Pages: 11

Gleaning Information From Proxy Statement; Reit Buy and Raising PT to $13

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Record: 40

05/09/2018

Company Report

Pages: 5

Business as Usual as the HAE Pipeline Continues to Progress

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00